Plummer-Vinson syndrome medical therapy

Plummer-Vinson syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Plummer-Vinson syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Plummer-Vinson syndrome medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Plummer-Vinson syndrome medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Plummer-Vinson syndrome medical therapy
CDC on Plummer-Vinson syndrome medical therapy
Plummer-Vinson syndrome medical therapy in the news
Blogs on Plummer-Vinson syndrome medical therapy
Directions to Hospitals Treating Plummer-Vinson syndrome
Risk calculators and risk factors for Plummer-Vinson syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

There is no treatment for [disease name]; the mainstay of therapy is supportive care.

OR

Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].

OR

The majority of cases of [disease name] are self-limited and require only supportive care.

OR

[Disease name] is a medical emergency and requires prompt treatment.

OR

The mainstay of treatment for [disease name] is [therapy].

OR   The optimal therapy for [malignancy name] depends on the stage at diagnosis.

OR

[Therapy] is recommended among all patients who develop [disease name].

OR

Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].

OR

Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].

OR

Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].

OR

Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Medical Therapy

The treatment of Plummer-Vinson syndrome is primarily aimed at correcting iron deficiency anemia. Patients with dysphagia may improve with iron replacement alone, if esophageal webs are not significantly obstructive.

Treatment is primarily aimed at correcting the iron-deficiency anemia. Patients with Plummer-Vinson syndrome should receive iron supplementation in their diet. This may improve dysphagia and pain.

• Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
• Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
• Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
• Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].

Disease Name

• 1 Stage 1 - Name of stage
  • 1.1 Specific Organ system involved 1
    • 1.1.1 Adult
      • Preferred regimen (1): drug name 100 mg PO q12h for 10-21 days (Contraindications/specific instructions)
      • Preferred regimen (2): drug name 500 mg PO q8h for 14-21 days
      • Preferred regimen (3): drug name 500 mg q12h for 14-21 days
      • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
      • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
      • Alternative regimen (3): drug name 500 mg PO q6h for 14–21 days
    • 1.1.2 Pediatric
      • 1.1.2.1 (Specific population e.g. children < 8 years of age)
        • Preferred regimen (1): drug name 50 mg/kg PO per day q8h (maximum, 500 mg per dose)
        • Preferred regimen (2): drug name 30 mg/kg PO per day in 2 divided doses (maximum, 500 mg per dose)
        • Alternative regimen (1): drug name10 mg/kg PO q6h (maximum, 500 mg per day)
        • Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
        • Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
      • 1.1.2.2 (Specific population e.g. 'children < 8 years of age')
        • Preferred regimen (1): drug name 4 mg/kg/day PO q12h（maximum, 100 mg per dose）
        • Alternative regimen (1): drug name 10 mg/kg PO q6h (maximum, 500 mg per day)
        • Alternative regimen (2): drug name 7.5 mg/kg PO q12h (maximum, 500 mg per dose)
        • Alternative regimen (3): drug name 12.5 mg/kg PO q6h (maximum, 500 mg per dose)
  • 1.2 Specific Organ system involved 2
    • 1.2.1 Adult
      • Preferred regimen (1): drug name 500 mg PO q8h
    • 1.2.2 Pediatric
      • Preferred regimen (1): drug name 50 mg/kg/day PO q8h (maximum, 500 mg per dose)

• 2 Stage 2 - Name of stage
  • 2.1 Specific Organ system involved 1

    Note (1):

    Note (2):

    Note (3):

    • 2.1.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
        • Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
        • Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
      • Oral regimen
        • Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
        • Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
        • Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
        • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
        • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
        • Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
    • 2.1.2 Pediatric
      • Parenteral regimen
        • Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
        • Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
        • Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day) '(Contraindications/specific instructions)'
      • Oral regimen
        • Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
        • Preferred regimen (2): drug name (for children aged ≥ 8 years) 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
        • Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
        • Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
        • Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
        • Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)
  • 2.2 Other Organ system involved 2

    Note (1):

    Note (2):

    Note (3):

    • 2.2.1 Adult
      • Parenteral regimen
        • Preferred regimen (1): drug name 2 g IV q24h for 14 (14–21) days
        • Alternative regimen (1): drug name 2 g IV q8h for 14 (14–21) days
        • Alternative regimen (2): drug name 18–24 MU/day IV q4h for 14 (14–21) days
      • Oral regimen
        • Preferred regimen (1): drug name 500 mg PO q8h for 14 (14–21) days
        • Preferred regimen (2): drug name 100 mg PO q12h for 14 (14–21) days
        • Preferred regimen (3): drug name 500 mg PO q12h for 14 (14–21) days
        • Alternative regimen (1): drug name 500 mg PO q6h for 7–10 days
        • Alternative regimen (2): drug name 500 mg PO q12h for 14–21 days
        • Alternative regimen (3):drug name 500 mg PO q6h for 14–21 days
    • 2.2.2 Pediatric
      • Parenteral regimen
        • Preferred regimen (1): drug name 50–75 mg/kg IV q24h for 14 (14–21) days (maximum, 2 g)
        • Alternative regimen (1): drug name 150–200 mg/kg/day IV q6–8h for 14 (14–21) days (maximum, 6 g per day)
        • Alternative regimen (2):  drug name 200,000–400,000 U/kg/day IV q4h for 14 (14–21) days (maximum, 18–24 million U per day)
      • Oral regimen
        • Preferred regimen (1): drug name 50 mg/kg/day PO q8h for 14 (14–21) days (maximum, 500 mg per dose)
        • Preferred regimen (2): drug name 4 mg/kg/day PO q12h for 14 (14–21) days (maximum, 100 mg per dose)
        • Preferred regimen (3): drug name 30 mg/kg/day PO q12h for 14 (14–21) days (maximum, 500 mg per dose)
        • Alternative regimen (1): drug name 10 mg/kg PO q6h 7–10 days (maximum, 500 mg per day)
        • Alternative regimen (2): drug name 7.5 mg/kg PO q12h for 14–21 days (maximum, 500 mg per dose)
        • Alternative regimen (3): drug name 12.5 mg/kg PO q6h for 14–21 days (maximum,500 mg per dose)

Food Sources of Iron

• Iron deficiency can have serious health consequences that diet may not be able to quickly correct.
• Iron supplementation is often necessary if iron deficiency is symptomatic. However, mild iron deficiency can be corrected, and prevented, by eating iron-rich foods.
  • Iron rich foods from plants and animals are absorbed and processed differently by the body.
  • Iron from meat (heme iron source) is more easily broken down and absorbed than iron in grains (nonheme iron source).
  • Minerals and chemicals in one type of food may inhibit absorption of iron from another type of food eaten at the same time.[2]
  • Heme-bound iron from animal source is readily absorbed as compared to iron from plant sources.
    • Thus, vegetarians and vegans should have a higher total daily iron intake than those who consume meat, fish or poultry.[3]
    • Legumes and dark-green leafy vegetables like broccoli, kale and oriental greens are especially good sources of iron for vegetarians and vegans. However, spinach and swiss chard contain oxalates which bind iron making it largely unavailable for absorption.
    • Iron from nonheme sources (foodgrains) is more readily absorbed if consumed with foods that contain either heme-bound iron or vitamin C.

Template:Col-2

Selected Food Sources of Heme Iron

Food	Serving size	Miligrams per serving	% DV*
Chicken liver (cooked)	3˝ ounces	12.8	70
Oysters(breaded and fried)	6 pieces	4.5	25
Beef, chuck (lean, braised)	3 ounces	3.2	20
Clams (breaded, fried)	1 cup	3.0	15
Beef tenderloin (roasted)	3 ounces	3.0	15
Turkey ( dark meat, roasted)	3˝ ounces	2.3	10
Beef, eye of round (roasted)	3 ounces	2.2	10
Turkey, light meat (roasted)	3˝ ounces	1.6	8
Chicken, leg, meat only (roasted)	3˝ ounces	1.3	6
Tuna, fresh bluefin (cooked)	3 ounces	1.1	6
Chicken breast (roasted)	3 ounces	1.1	6
Halibut (cooked)	3 ounces	0.9	6
Blue crab (cooked)	3 ounces	0.8	4
Pork loin (broiled)	3 ounces	0.8	4
Tuna white (canned in water)	3 ounces	0.8	4
Shrimp (mixed species, cooked)	4 large	0.7	4

Selected Food Sources of Nonheme Iron

Food	Serving size	Miligrams per serving	% DV*
Ready-to-eat cereal (100% iron fortified	cup	18.0	100
Oatmeal, instant, fortified (prepared with water	1 cup	10.0	60
Soybeans, mature (boiled)	1 cup	8.8	50
Lentils (boiled)	1 cup	6.6	35
Kidney beans mature (boiled)	1 cup	5.2	25
Lima beans large, mature (boiled)	1 cup	4.5	25
Navy beans mature (boiled)	1 cup	4.5	25
Ready-to-eat cereal (25% iron fortified)	1 cup	4.5	25
Black beans mature (boiled)	1 cup	3.6	20
Pinto beans mature (boiled)	1 cup	3.6	20
Molasses (blackstrap)	1 tablespoon	3.5	20
Tofu (raw, firm)	˝ cup	3.4	20
Spinach (boiled, drained)	˝ cup	3.2	20
Spinach (canned, drained solids)	˝ cup	2.5	10
Black-eyed peas (cowpeas) (boiled)	˝ cup	1.8	10
Spinach (frozen, chopped, boiled)	˝ cup	1.9	10
Grits (white, enriched	1 cup	1.5	8
Raisins (seedless, packed)	˝ cup	1.5	8
Whole wheat bread	1 slice	0.9	6
White bread (enriched)	1 slice	0.9	6